Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy

* Diagnosis of malignant disease * No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide \[AC\]) * Cisplatin at a dose of ≥70mg/m\^2, with or without other chemotherapy agent(s) OR * Anthracycline (60 mg/m\^2) plus cyclophosphamide(600 mg/m\^2) * Age ≥18 years * Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2 * Required Initial Laboratory Values ≤ 120 days prior to registration * Serum Creatinine ≤2.0 mg/dL * Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN) * Absolute neutrophil count (ANC) ≥1500/mm\^3 * No nausea or vomiting ≤ 24 hours prior to registration * Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion) * No severe cognitive compromise * No known history of CNS disease (e.g. brain metastases, seizure disorder) * No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy * No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy) * No concurrent use of amifostine * No concurrent abdominal radiotherapy * No concurrent use of quinolone antibiotic therapy * No chronic alc…